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ABSTRACT Althoughhighlyeffectiveinthegeneralpopulationwhenwellmatchedtocirculatinginﬂuenzavirusstrains,current
inﬂuenzavaccinesarelimitedintheirutilityduetothenarrowbreadthofprotectiontheyprovide.Thestrainspeciﬁcityofvac-
cinespresentlyinusemirrorstheexquisitespeciﬁcityoftheneutralizingantibodiesthattheyinduce,thatis,antibodieswhich
bindtothehighlyvariableglobularheaddomainofhemagglutinin(HA).Herein,wedescribetheconstructionofanovelim-
munogencomprisingtheconservedinﬂuenzaHAstalkdomainandlackingtheglobularhead.Vaccinationofmicewiththis
headlessHAconstructelicitedimmuneserawithbroaderreactivitythanthoseobtainedfrommiceimmunizedwithafull-length
HA.Furthermore,theheadlessHAvaccineprovidedfullprotectionagainstdeathandpartialprotectionagainstdiseasefollow-
inglethalviralchallenge.OurresultssuggestthattheresponseinducedbyheadlessHAvaccinesissufﬁcientlypotenttowarrant
theirfurtherdevelopmenttowardauniversalinﬂuenzavirusvaccine.
IMPORTANCE Currentinﬂuenzavaccinesareeffectiveagainstonlyanarrowrangeofinﬂuenzavirusstrains.Itisforthisreason
thatnewvaccinesmustbegeneratedandadministeredeachyear.Wenowreportprogresstowardthegoalofaninﬂuenzavirus
vaccinewhichwouldprotectagainstmultiplestrains.Ourapproachisbasedonpresentationtothehostimmunesystemofa
regionoftheinﬂuenzavirus—calleda“headlesshemagglutinin”(headlessHA)—whichissimilaramongamultitudeofdiverse
strains.WeshowthatvaccinationofmicewithaheadlessHAconfersprotectiontotheseanimalsagainstalethalinﬂuenzavirus
challenge,therebydemonstratingtheviabilityoftheapproach.Throughfurtherdevelopmentandtesting,wepredictthatasin-
gleimmunizationwithaheadlessHAvaccinewilloffereffectiveprotectionthroughseveralinﬂuenzaepidemics.
Received 28 January 2010 Accepted 29 January 2010 Published 18 May 2010
Citation Steel, J., A. C. Lowen, T. T. Wang, M. Yondola, Q. Gao, et al. 2010. An inﬂuenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1(1):e00018-10.
doi:10.1128/mBio.00018-10.
Editor Terence Dermody, Vanderbilt University Medical Center
Copyright © 2010 Steel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial Share-Alike 3.0 Unported
License, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.
Address correspondence to Peter Palese, peter.palese@mssm.edu.
I
nﬂuenza in humans is a respiratory disease that ranges in sever-
ity from subclinical infection to primary viral pneumonia,
whichcanresultindeath.Theclinicaleffectsofinfectionvarywith
thevirulenceoftheinﬂuenzastrainandtheexposurehistory,age,
and immune status of the host. The cumulative morbidity and
mortality caused by seasonal inﬂuenza are substantial due to the
relatively high attack rate: in the United States, inﬂuenza viruses
infect an estimated 10% to 15% of the population (1, 2) and are
associated with approximately 30,000 deaths each year (3, 4). In
addition to causing annual epidemics, inﬂuenza viruses are the
cause of infrequent pandemics. Due to the lack of preformed im-
munity against the major viral antigen (hemagglutinin [HA]),
pandemicinﬂuenzacanaffectmorethan50%ofthepopulationin
a single year and often causes more severe disease than epidemic
inﬂuenza. A stark example is the pandemic of 1918, in which an
estimated 50 to 100 million people were killed (5).
Themosteffectivewaytoprotectagainstinﬂuenzavirusinfec-
tion is through vaccination; however, current vaccination ap-
proaches rely on achieving a good match between circulating
strains and the isolates included in the vaccine. Such a match is
often difﬁcult to attain due to a combination of factors. First,
inﬂuenza viruses are constantly undergoing change: every 3 to
5yearsthepredominantstrainsofinﬂuenzaAvirusesarereplaced
byvariantsthathaveundergonesufﬁcientantigenicdrifttoevade
existing antibody responses (6). Isolates to be included in vaccine
preparations must therefore be selected each year based on the
intensive surveillance efforts of the WHO collaborating centers.
Second, to allow sufﬁcient time for vaccine manufacture and dis-
tribution, strains must be selected approximately 9 months prior
to the initiation of the inﬂuenza season. Unfortunately, the pre-
dictions of the vaccine strain selection committee can be inaccu-
rate, resulting in a substantial drop in the efﬁcacy of vaccination
(7, 8).
Herein, we describe a novel inﬂuenza vaccine construct which
isbasedonaconservedregionoftheHAprotein.Therationalefor
ourapproachfollows(orbuildson)fromanearliereffortreported
in 1983 (9), which in turn was prompted by our realization that
the HA2 subunit of the inﬂuenza virus hemagglutinin is relatively
wellconserved(10).Wereasonedthatantiseraelicitedagainstthe
HA2 protein should be cross-reactive between strains and poten-
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cination with conventional inﬂuenza vaccines, HA2 is thought to
be masked by the membrane-distal portion of HA, a bulky and
highlyimmunogenicglobularheaddomain.Withtheaimofpro-
ducing a vaccine which would elicit cross-reactive anti-HA2 anti-
bodies, we therefore derived a method of chemically treating pu-
riﬁedinﬂuenzavirionsinordertoremovetheHA1subunit.While
immunizationofrabbitsormicewithsubviralparticlesproduced
in this way yielded a strong humoral response against HA2, this
response was not found to be protective against inﬂuenza viral
challenge (9). In the context of the H2 subtype, a truncated hem-
agglutinin molecule lacking a signiﬁcant portion of the globular
headhasbeenshowntoofferprotectiontomiceuponsubsequent
challenge with inﬂuenza virus. In animals vaccinated with the
truncated HA, 7 out of 10 mice were protected from death, while
in mock vaccinated animals only 1 out of 10 mice survived infec-
tion(28).Sincethattime,weandothershaveidentiﬁedmonoclo-
nal antibodies (MAbs) which bind the HA stalk domain and are
both broadly cross-reactive and neutralizing (11–14). In light of
our earlier efforts to raise immune sera against HA2, a key feature
of these antibodies is that they map to epitopes which comprise
membrane-proximal portions of both the HA1 and HA2 sub-
units. Using modern molecular techniques, we have now identi-
ﬁed a way of expressing a modiﬁed HA molecule which lacks the
globular head domain and maintains the integrity of the stalk
region,includingboththeHA1andHA2portions.Vaccinationof
mice with such a headless HA immunogen elicited antisera that
were cross-reactive against multiple subtypes of hemagglutinin
and furthermore was found to provide protection against lethal
inﬂuenza virus challenge. Our data suggest that, through optimi-
zation of antigen delivery and immunogenicity, a headless HA
molecule could form the basis for a broadly protective inﬂuenza
virus vaccine.
RESULTS
Design and construction of headless HA constructs. We sought
to generate an immunogen consisting of the complete HA2
polypeptide and the regions of HA1 contributing to the stalk re-
gion but lacking the globular head domain of HA1. With this aim
in mind, we noted the existence of a conserved disulﬁde bond
linking cysteines 52 and 277 (H3 numbering) of HA1. The loop
ﬂanked by these two cysteines comprises the bulk of the globular
head domain, while the N-terminal 51 and the C-terminal
52aminoacidsofHA1extenddownwardfromthecysteinebridge
and contribute to the stalk region. Due to the proximity of cys-
teines52and277inthethree-dimensionalstructureofHA(Fig.1)
(15),wepredictedthatreplacementoftheinterveningloopwitha
short linker peptide would not disrupt the folding of the remain-
derofthemolecule.Basedonthisprinciple,wedesignedapanelof
headless HA constructs (Fig. 1). First, sequences encoding linker
peptidesoftwoglycines(2G),fourglycines(4G),oraprolineand
a glycine (PG) were inserted into the open reading frames of the
A/PuertoRico/8/1934(H1N1)(PR8)andtheA/HongKong/1968
(H3N2) (HK68) hemagglutinins in place of the respective nucle-
otide sequences encoding amino acids 53 to 276. These three
linker peptides were selected to have a range of ﬂexibilities, with
4GpredictedtobethemostﬂexibleandPGthemostrigid.Totest
whether insertion of a linker in the absence of a disulﬁde bond at
thispositionwouldyieldamorestableproduct,wedesignedthree
additional constructs in the context of the PR8 HA: sequences
encoding one, two, or three glycines were inserted in place of the
sequences encoding amino acids 52 to 277 (that is, both the cys-
teines and the connecting loop were replaced). Based on the hy-
pothesis that glycosylation may improve trafﬁcking through the
Golgi complex, we also tested the insertion of a glycosylation site
(Asn-Ala-Ser) in place of amino acids 52 to 277 in both the PR8
and HK68 backgrounds. Finally, a series of three constructs was
made in each of the PR8 and HK68 HAs in which existing wild-
typeaminoacidsweredirectlylinked:aminoacids51to278,51to
279, or 50 to 280. Constructs were made in the context of an H1
(representative of group 1) and an H3 (representative of group 2)
HA,sincetheactivityofneutralizingantibodiestargetingthestalk
region appears to be limited to HA subtypes within the same ma-
jor phylogenetic group (11–14).
ExpressionofheadlessHAconstructsintransfectedcellcul-
tures.Asapreliminarytestofproteinintegrityandstability,levels
of the headless HA constructs expressed in transiently transfected
cellswereassessedbyWesternblotting.AsshowninFig.2A,head-
lessHAconstructsbasedonthePR8HAproteinwereexpressedto
levelscomparabletothecorrespondingfull-lengthproteinat24h
posttransfection. Within the panel of constructs tested, those
which retained Cys 52 and Cys 277 and carried the linker peptide
2G, 4G, or PG exhibited the highest steady-state levels. In the
context of the HK68 HA (Fig. 2B), similar results were seen: all
HK68 headless HAs tested were detected using an antibody spe-
ciﬁc to the stalk domain, and those carrying the 2G, 4G, or PG
linker between Cys 52 and Cys 277 were the most abundant. For
both HK68 and PR8, the least abundant constructs were those
with the direct linkage between amino acids 50 and 280 and those
with the inserted glycosylation site (Fig. 2).
To test whether the headless HA constructs were also being
transported to the cell surface, ﬂuorescence-activated cell sorter
(FACS) analysis of transiently transfected 293T cells was per-
formed following surface staining with HA2-speciﬁc antibodies.
Only the 2G, 4G, and PG constructs, which showed high levels of
protein expression by Western blotting, were tested in this assay.
As shown in Fig. 3, the three PR8-based constructs and the three
HK68-based constructs were detected, indicating that transport
throughtheGolgicomplextothecellsurfacewasnotdisruptedby
removal of the globular head domain. No marked differences
among the three linker bridges were noted in either the Western
blotting or FACS-based assays. The constructs carrying the 4G
linker bridge were selected for further characterization.
Incorporation of headless HA into VLPs. As a further test of
the functionality of the headless HA molecules, we assessed their
ability to bud from the cell surface to produce virus-like particles
(VLPs). While transient expression of the headless HA constructs
alone in 293T cells was not found to result in VLP production
(data not shown), cotransfection with an HIV Gag-based con-
struct did lead to the production of headless HA-containing par-
ticles. Speciﬁcally, when either the PR8 or HK68 4G headless HA
construct was coexpressed in 293T cells with a Gag-EGFP (en-
hanced green ﬂuorescent protein) fusion protein, particles capa-
bleofsedimentingthrougha30%sucrosecushionandcontaining
headless HA proteins were released into the cell culture medium
(Fig. 4). Similar results were obtained in the presence (Fig. 4) or
absence (data not shown) of exogenous trypsin. Unlike the full-
lengthHAprotein,andasexpectedbasedonthelackofaglobular
head domain, the release of headless HA-containing particles
was not found to be dependent on the presence of neuraminidase
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carry full-length HA proteins was provided by the inclusion of an
expression vector encoding the cognate NA protein in the respec-
tive transfections. The presence of NA in the PR8 full-length HA
VLPs is visible in Fig. 4 due to the use of a polyclonal antiserum.
Vaccination with the PR8 headless HA provides protection
againsthomologouschallengeinmice.Thepotentialofvaccina-
tion with a headless HA construct to induce a protective immune
response was evaluated in the mouse model. The following three-
dose vaccine regimen was used: mice received plasmid DNA on
HA2 HA1     
Signal peptide Transmembrane domain
Cytoplasmic tail
Fusion peptide
Full-length HA:
Headless HA:
HA2
A
PR8 linker sequences
2G: KLCGGCNTK
4G: KLCGGGGCNTK
PG: KLCPGCNTK
No Cys 1G: KLGNTK
No Cys 2G: KLGGNTK
No Cys 3G: KLGGGNTK
No Cys: KLNTK
No Cys ∆1: KLTK
No Cys ∆3: KK
No Cys NAS: KLNASNTK
HK68 linker sequences
2G: KICGGCISE
4G: KICGGGGCISE
PG: KECPGCISE
No Cys: KIISE
No Cys ∆1: KISE
No Cys ∆3: KE
No Cys NAS: KINASNTK
PR8 HA HK68 HA PR8 Headless HA HK68 Headless HA
B
FIG1 SchematicofheadlessHAconstructs.(A)Schematicofthelinearstructureofthefull-lengthinﬂuenzavirusHAprotein(top)andageneralizedheadless
HAprotein(bottom).LinkerpeptidestestedinthecontextofthePR8andHK68HAsequencesareshown.Insertedaminoacidsareshowninboldredtype,while
amino acids present in the native HA sequence are in black. (B) Schematic of the folded structures of the full-length and headless HAs of PR8 virus (left panel)
and HK68 virus (right panel). In both cases, headless HAs carrying the 4G linker bridge are depicted. The HA1 subunit is blue, and the HA2 subunit is green.
Cysteines52and277areshowninyellow,and4Glinkersequencesareshowninred.Thefull-lengthHAstructuresweredownloadedfromtheProteinDatabase
(PDB):PR8HA(PDBID1RVX)andHK68HA(PDBID1MQN).SchematicsofheadlessHAsweregeneratedusingthefull-lengthHAcoordinatesasastarting
point,and4GloopsweremanuallydockedintotheheadlessHAcarbontoclosethediscontinuousalpha-carbonaminoacidchain.Finalimagesweregenerated
with PyMol (Delano Scientiﬁc).
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adjuvant on day 56. Each DNA vaccine comprised pGag-EGFP
alone or in combination with a protein expression vector encod-
ingthePR8full-lengthHA,thePR84GheadlessHA,ortheHK68
4G headless HA and was administered intramuscularly with elec-
troporation. For a ﬁnal boost, VLP preparations with an HA con-
tent of 150 ng (or an equivalent amount of Gag-only VLP) were
combined with Freund’s complete adjuvant and administered in-
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FIG2 Expression of headless HA constructs in transiently transfected cells. Headless HA constructs were expressed in 293T cells by plasmid transfection in the
absence of exogenous trypsin. At 24 h posttransfection, whole-cell lysates were prepared and subjected to sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) followed by Western blotting. HA proteins were detected using the polyclonal antiserum 3951 (for PR8) or the MAb 12D1 (for HK68).
Molecular mass markers in kilodaltons are shown to the left of each blot, and transfected constructs are identiﬁed above the appropriate lane. Mock, untrans-
fected cells; full, full-length HA protein. For the headless HA constructs, the amino acid sequence bridging the N- and C-terminal strands of HA1 is shown.
Boldfacelettersindicateinsertedaminoacids,whilelightfacelettersrepresentresiduespresentinthewild-typeHA.IntheregionoftheCys52toCys277disulﬁde
bond, the wild-type sequences are as follows: for PR8, K50L51C52... C 277N278T279K280; for HK68, K50I51C52...C 277I278S279E280. (A) PR8-based constructs; (B)
HK68-based constructs. In panel B, the molecular weight of the full-length HK68 HA0 protein is indicated by an arrow.
FIG 3 Detection of headless HA proteins on the surfaces of transfected cells. Full-length and headless HA constructs were expressed in 293T cells by plasmid
transfection.At24hposttransfection,cellsweretrypsinizedandHAproteinsonthecellsurfacewerestainedusingpolyclonalantiserum3951(forPR8)orMAb
12D1 (for HK68) before analysis by ﬂow cytometry. (A) Mock-transfected cells stained with immune serum 3951 (gray) are compared to cells transfected with
pDZPR8HA(red)orcellstransfectedwithpCAGGSPR82G,4G,orPGheadlessHAconstructs(blue).(B)Mock-transfectedcellsstainedwithMAb12D1(gray)
are compared to cells transfected with pCAGGS HK68 HA (orange) or cells transfected with pCAGGS HK68 2G, 4G, or PG headless HA constructs (green).
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4 mbio.asm.org April 2010 Volume 1 Issue 1 e00018-10traperitoneally to each mouse. The VLPs used for this purpose
were produced in the absence of trypsin and comprised Gag-
EGFP alone or in combination with full-length PR8 HA and PR8
NA, the PR8 4G headless HA, or the HK68 4G headless HA. On
day77,micewerechallengedintranasallywithPR8virusandthen
monitored daily for morbidity and mortality for 10 days. In the
Gag-only-vaccinated group, three out of four mice lost 25% of
their initial body weight and were therefore scored as dead, and
thefourthanimalwasseentolose15%ofitsinitialbodyweight.In
contrast, all mice vaccinated with the PR8 4G headless HA sur-
vivedandexperiencedamaximumaverageweightlossofonly6%
(Fig. 5).
Vaccination of mice with the PR8 headless HA elicits cross-
reactive antisera. The reactivity of serum collected from vacci-
nated mice against inﬂuenza virus HA proteins was assessed by
hemagglutination inhibition (HAI) assay, neutralization assay,
and enzyme-linked immunosorbent assay (ELISA). As expected
based on the absence of a globular head domain in the vaccine
constructs,thepooledserafrommiceimmunizedwithGagalone,
the HK68 4G headless HA, or the PR8 4G headless HA did not
show HAI activity against PR8 virus before challenge. In contrast,
prechallenge sera obtained from mice that received the PR8 full-
length-HA vaccine, as well as all postchallenge sera, were strongly
reactiveagainstPR8virusintheHAIassay(Table1).InanMDCK
cell-basedneutralizationassay,pooledserumcollectedfrommice
immunized with PR8 full-length HA exhibited potent neutraliz-
ing activity, whereas that collected from PR8 4G-vaccinated mice
showed marginally higher activity than the control sera derived
fromGag-only-orHK684G-vaccinatedmice(Table1).Thus,the
presenceofneutralizingantibodiesintheseraofmiceimmunized
with PR8 headless HA was not conclusively demonstrated.
By ELISA, prechallenge sera were tested against a panel of HA
substrates in order to evaluate the breadth of reactivity (Fig. 6).
Against concentrated PR8 virion (Fig. 6A), Gag-only and HK68
4G antisera showed only a low level of background activity at the
lowest dilution (1:50), while sera from the animals vaccinated
with PR8 full-length HA gave a positive signal at a 1:6,250 dilu-
tion. Antisera against the PR8 4G headless HA were less potent
than those against the full-length HA but reacted positively at a
1:50 dilution. When tested against recombinant HA proteins de-
rived from a recent seasonal H1N1 inﬂuenza virus (A/New Cale-
donia/20/1999) (Fig. 6B) and a 2009 pandemic H1N1 inﬂuenza
virus (A/California/04/2009) (Fig. 6C), Gag-only and HK68 4G
antiserawerenegative,whileserafrommicethatreceivedthePR8
full-length HA were either negative or showed a low level of reac-
tivity. On these heterologous H1 substrates, the PR8 4G antisera
showed the highest levels of reactivity, with the sera from two of
the ﬁve mice in particular demonstrating high titers. Similar re-
sults were seen with recombinant HA proteins of the H2 and H5
subtypes: against the A/Singapore/1/1957 (H2N2) and A/Viet
Nam/1203/2004 (H5N1) HAs, sera derived from PR8 4G-
vaccinatedmiceshowedmoderatetohighactivity,whileserafrom
the remaining groups (including those receiving the full-length
HA) were largely negative (Fig. 6D and E). Finally, against the H3
subtype HA of A/Hong Kong/1/1968 (H3N2), only the HK68 4G
antisera produced a positive signal (Fig. 6F). Thus, overall, sera
obtainedfrommicevaccinatedwiththeheadlessPR8HAshowed
greater activity against heterologous strains than did sera from
animalsvaccinatedwithPR8full-lengthHA.Whileserumtitersof
PR8 4G-vaccinated mice appeared to be higher against the heter-
ologous HA proteins than against the homologous PR8 virus, a
direct comparison should not be made due to the differing sub-
strates used (puriﬁed HA versus whole virus). Within the PR8 4G
group, the sera from two mice in particular consistently showed
relativelyhightitersbyELISA.Theseserologicﬁndingscorrelated
with the protection data in that these same two mice were fully
protected from disease while their three remaining counterparts
each exhibited some weight loss after challenge (data not shown).
HK68 4G
HK68 HA & NA
HA0
headless HA0
HA2
PR8 4G
PR8 HA & NA
HA0
NA
HA2
FIG 4 Incorporation of headless HA proteins into VLPs. The HA content of
VLPs generated by cotransfection of HA constructs with pGag-EGFP was as-
sessed by Western blotting. PR8-based VLPs were probed with polyclonal
antiserum 3951, and HK68-based proteins were detected with MAb 12D1.
Bandsareidentiﬁedtotherightofeachblot.NotethatVLPswereproducedin
thepresenceofexogenoustrypsin,resultinginthecleavageofHA0toproduce
HA1(notvisualizedhere)andHA2.EachlaneshowsVLPsharvestedfromthe
equivalent of one 10-cm dish.
FIG 5 Vaccination of mice with headless HA constructs provides protection
from death. The average body weight loss in each group of vaccinated mice
following challenge with PR8 virus is shown. Error bars represent standard
deviations. A star indicates the death of a mouse.
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We describe a novel inﬂuenza vaccine construct which lacks the
highly immunogenic globular head of the HA protein and is
thereby designed to present the conserved HA stalk region to im-
munecells.Weshowthatthisconstructcanbestablyexpressedin
mammalian cells and is targeted to the cell surface in a manner
similar to that of full-length HA proteins. Our observations to
dateindicatethatheadlessHAproteinscannotbudindependently
to form VLPs. Provision of the HIV Gag protein did, however,
allow incorporation of headless HA molecules into VLPs, a ﬁnd-
ing which we have exploited to produce VLP-based vaccines. Im-
munization of mice with a PR8-based headless HA construct in
plasmid DNA and VLP formats provided full protection against
death and partial protection against weight loss following a lethal
homologous challenge.
WhilevaccinationwiththePR8full-lengthHAofferedahigher
degreeofprotectionthanvaccinationwithaPR8headlessHA,this
observation was not unexpected. The inclusion of the PR8 NA
protein in VLPs administered to mice vaccinated with PR8 full-
length HA may have contributed to the protection seen: antibod-
iesagainstNAarelikelytohavebeenelicitedandwouldhavebeen
activeuponchallengewiththewild-typePR8virus.Perhapsmore
importantly, however, the globular head domain of HA is well
recognized to include the major protective antigens of inﬂuenza
viruses (16). This region of the virus is highly immunogenic and
therefore elicits high serum antibody titers. As a result of their
ability to block attachment to host cell receptors, these antibodies
are furthermore often potently neutralizing. If a sufﬁciently po-
tent humoral response against the HA stem can be attained, how-
ever, protection extending to multiple strains would be expected
due to the high sequence conservation of this region. Thus, an
immunogenic vaccine which presents the HA stalk domain such
that it is accessible to B cells is an important step toward the de-
velopment of a broadly protective inﬂuenza vaccine. Our results
herein with homologous viral challenge indicate that a headless
HA vaccine is sufﬁciently immunogenic to induce protective im-
munity.
The 16 hemagglutinin subtypes of inﬂuenza A viruses fall into
twomajorphylogeneticgroupings,identiﬁedasgroup1(H1,H2,
H5, H6, H8, H9, H11, H12, H13, and H16) and group 2 (H3, H4,
H7, H10, H14, and H15). As underlined by the ability of MAbs
describedbyKashyapetal.(12)andMAbsC179,F10,andCR6261
(11, 13, 14) to cross-react with group 1, but not group 2, HAs, the
sequenceandstructureoftheHAstalkdomaindiffersigniﬁcantly
betweenthetwogroups.Forexample,thePR8headlessHAshares
only49%identitywiththeHK68headlessHAbut95%,77%,and
75% identity, respectively, with the corresponding regions of the
driftedH1A/NewCaledonia/20/1999HA,theH2A/Singapore/1/
1957HA,andtheH5A/VietNam/1203/2004HA.Consistentwith
this lack of conservation between H1 and H3 HAs in the targeted
region, vaccination of mice with an HK68 headless HA construct
didnotelicitantiserathatwerecross-reactivewithgroup1HAsor
provide protection against PR8 challenge. Whether immuniza-
tion with the HK68 construct will offer protection against chal-
lenge with H3 and possibly other group 2 subtype inﬂuenza vi-
ruses remains to be determined. It is encouraging to note,
however,thatcharacterizationofthe12D1MAb,whichhascross-
neutralizing activity against H3 HAs representing 40 years of an-
tigenic drift, has mapped its binding site to the stalk domain (17).
Thus,epitopeswhichelicitbroadlyreactive,neutralizingantibod-
ies are present not only in group 1, but also in group 2, HA stalk
domains.
The protection seen following vaccination with the PR8 head-
less HA raises the question of why a vaccine comprising inﬂuenza
virions stripped of HA1 did not provide a similar level of protec-
tion (9). We believe the key difference between the two ap-
proachesisintheconformationoftheHA.Inourearlierattempts,
acid and dithiothreitol (DTT) treatments were used to remove
HA1 from the viral surface; thus, the remaining HA2 portion of
the molecule was in the extended, low-pH conformation (16).
SinceitisexpressedunderneutralpHconditionsandsuchthatthe
terminal strands of HA1 remain covalently linked to HA2, we
expect that the headless HAs described herein remain in the pre-
fusionconformationasdepictedinFig.1B.Antibodieswhichbind
to the stalk and prevent infection are more likely to be elicited by
a molecule in the prefusion form.
AmongtheﬁvemicevaccinatedwithPR84GheadlessHA,two
were seen to develop relatively high cross-reactive antibody titers
and were fully protected from disease, while the remaining three
showedserumtitersonlymarginallyabovebackgroundandsome
weight loss upon challenge. These results suggest that the vaccine
dose used (particularly, we think, for the VLP boost at 150 ng HA
per mouse) may have been at a borderline level required for full
protection,suchthattheoutcomewassubjecttostochasticeffects.
To address this problem, approaches are now being explored to
increase yields of headless HA protein, either in the context of
VLPs or as recombinant protein.
EarlierreportshaveindicatedthatantibodiestargetingtheHA
stalk domain are able to neutralize virus infectivity by blocking
fusion (11, 13, 14). The protection against challenge observed in
vaccinated mice suggests that such fusion-inhibiting antibodies
mayhavebeenelicitedbythePR8headlessHAvaccine;conclusive
evidenceforthepresenceofsuchantibodiesbyinvitroneutraliza-
tion has proven to be technically challenging, however, due to the
high limit of detection of the assay. Serologic analysis by ELISA
did,however,revealthatthePR84GheadlessHAvaccine,butnot
the PR8 full-length HA vaccine, induced antibodies which are
cross-reactiveamonggroup1HAsubtypes.Thisﬁndingsupports
TABLE 1 HAI and neutralizing activity in immune sera of vaccinated mice
Vaccine
HAIa
Neutralization
postvaccinationb Postvaccination Postchallenge
Gag only 8 1:20
HK68 4G headless HA plus Gag 1 8 1:20
PR8 4G headless HA plus Gag 1 8 1:40
PR8 full-length HA plus Gag 128 128 1:20,480
a The fold increase in titer over Gag-only prechallenge serum is shown.
b The highest dilution of serum which achieved at least 50% neutralization is shown.
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FIG 6 Antisera from mice vaccinated with the PR8 4G headless HA show broad cross-reactivity by ELISA. The vaccine groups from which sera are derived are
identiﬁedatthetopofeachcolumn,andtheELISAsubstrateusedisindicatedtotherightofeachrow.Thecolorsusedareconsistentthroughouttheﬁgure,with
serafromGag-only-vaccinatedmiceindicatedinblack,HK684G-vaccinatedmiceindicatedingreen,PR84G-vaccinatedmiceindicatedinblue,andfull-length-
PR8-HA-vaccinatedmiceindicatedinred.Eachmouseisrepresentedbyauniquesymbolthatisthesameineachpanel.Arabbitantiserumraisedagainstwhole
PR8virusisshowningraywithopentriangles,andaserumsampletakenfromanaivemouseisshowningraywithopensquares.Thereactivitiesofmousesera
to whole PR8 virus (A), puriﬁed recombinant A/New Caledonia/20/1999 HA protein (B), puriﬁed recombinant A/California/04/2009 HA (C), puriﬁed recom-
binantA/Singapore/1/1957HA(D),puriﬁedrecombinantA/VietNam/1203/2004HA(E),andpuriﬁedrecombinantA/HongKong/1/1968HA(F)areshown.
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moleculeinhibitsrecognitionofthestemregionbyimmunecells,
either through steric shielding or due to the immune dominance
ofthemembrane-distalportionoftheprotein.Thesedatafurther-
more suggest that vaccination with a headless HA may lead to
protection against divergent inﬂuenza strains.
MATERIALS AND METHODS
Plasmids. pGag-EGFP was generously provided by Carol Carter, Stony
Brook University (18). The pCAGGS expression plasmid was kindly pro-
vided by J. Miyazaki, Osaka University (19). The plasmids pDZ PR8 HA
and pDZ PR8 NA were constructed as described previously (20). For the
construction of pCAGGS HK68 HA and pCAGGS HK68 NA, viral genes
werereversetranscribed(Transcriptorreversetranscriptase;Roche)from
puriﬁedvirionRNA,ampliﬁed(PFUTurbo;Stratagene),andclonedinto
the vector pPOL1 (21) by following the recombinational protocol de-
scribed by Wang et al. (22). Protein coding regions were then ampliﬁed
with primers carrying the appropriate restriction enzyme sites and sub-
cloned into the multiple-cloning site of pCAGGS between the NotI and
NheI sites. Headless HA constructs were generated by either excise or
fusion PCR methods. Excise PCR was performed on the pPOL1 PR8 HA
orpPOL1HK68HAplasmids.TheresultingPCRproductswerecircular-
ized by ligation, and the open reading frame of the headless HA was then
subcloned into pCAGGS at the NotI and NheI sites. Fusion PCR was
performed on pDZ PR8 HA or pCAGGS HK68 HA plasmid templates,
and products were inserted into pCAGGS at the NotI and NruI sites.
Primer sequences are available on request.
Antibodies. MAb 12D1 was generated by sequential intramuscular
immunization of BALB/c mice with plasmid DNAs encoding the HK68
HA, the A/Alabama/1/1981 (H3N2) HA, and the A/Beijing/46/1992
(H3N2) HA, followed by a boost with whole A/Wyoming/03/2003
(H3N2)virus.ThisMAbbindsmultipleH3HAproteinsandmapstothe
HA2 subunit (17). Since a similar monoclonal antibody was not readily
availablefordetectionofthePR8headlessHAs,arabbitpolyclonalserum,
3951, was used. The polyclonal serum 3951 was raised against PR8 virus
from which the HA1 subunit had been removed by treatment with acid
and DTT (9) and therefore detects all viral structural proteins with the
exception of the HA1 subunit of HA.
Cells and viruses. 293T cells were obtained from the ATCC and were
maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco)
supplemented with 10% fetal bovine serum (FBS; Clontech). Madin-
Darby canine kidney cells were maintained in minimal essential medium
supplemented with 10% FBS (Clontech), 100 U/ml of penicillin, and
100 g/ml of streptomycin.
InﬂuenzaA/PuertoRico/8/1934(H1N1)viruswasobtainedbyreverse
genetics as previously described (23) using plasmids bearing the eight
genes deﬁned by accession numbers AF389115 to AF189122 (A/Puerto
Rico/8/34/MountSinai)intheNCBIdatabase.Theviruswasampliﬁedin
10-to11-day-oldembryonatedchickenseggsandtitratedbyplaqueassay.
Western blotting. To assess the expression levels of HA-based pro-
teins, 293T cells were transfected with 2 g of the appropriate plasmid
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions.At24hposttransfection,cellswerelysedin2proteinload-
ing buffer (125 mM Tris-HCl [pH 6.8], 4% sodium dodecyl sulfate, 20%
glycerol, 10% -mercaptoethanol, and 0.1% bromophenol blue). Lysates
were heated at 100°C for 5 min and then separated on a 10% sodium
dodecyl sulfate-polyacrylamide gel and transferred to a nitrocellulose
membrane (Whatman, Inc.). To detect HA-based proteins in VLP prep-
arations, pelleted VLPs were suspended in phosphate-buffered saline
(PBS), lysed through 1:1 mixing with 2 protein loading buffer, boiled
for5min,separatedona10%sodiumdodecylsulfate-polyacrylamidegel,
and transferred to a nitrocellulose membrane. Membranes were then
probed with MAb 12D1 or 3951 antiserum at a 1:2,000 dilution.
Flowcytometricanalysis.ToassesslevelsofHA-basedproteinsatthe
cell surface, 293T cells were transfected with 1 g of the appropriate plas-
midusingLipofectamine2000(Invitrogen)accordingtothemanufactur-
er’s instructions. At 24 h posttransfection, cells were trypsinized and re-
suspended in PBS containing 2% FBS prior to staining them with 3951
antiserum at a 1/250 dilution or with MAb 12D1 at a 1/200 dilution.
Stained cells were enumerated on a Beckman Coulter Cytomics FC 500
ﬂow cytometer, and the results were analyzed using FlowJo software.
Generation of VLPs. For the production of VLPs, 6  106 293T cells
wereseededintoa10-cmdishin8mlofDMEMwith10%FBS.Whilestill
in suspension, cells were transfected with Lipofectamine 2000 (Invitro-
gen) combined with the desired plasmid DNAs at a 4:1 ratio and as de-
scribedinthemanufacturer’sinstructions.TheamountsofplasmidDNA
used were as follows: for Gag-only VLPs, 7.5 g pGag-EGFP was trans-
fected; for Gag plus PR8 4G VLPs, 4.5 g of pGag-EGFP plus 4.5 go f
pCAGGS PR8 4G was used; for Gag plus HK68 4G VLPs, 4.5 g of pGag-
EGFP plus 4.5 g of pCAGGS HK68 4G was used; and for Gag plus PR8
HAplusPR8NAVLPs,3gofpGag-EGFPwascombinedwith3geach
of pDZ PR8 HA and pDZ PR8 NA. At 6 h posttransfection, medium was
changed to fresh DMEM containing 10% FBS or to Opti-MEM (Gibco)
supplemented with 3% bovine serum albumin (Sigma) and 10 g/ml
TPCK (N-p-tosyl-L-phenylalanine chloromethyl ketone)-treated trypsin
(Sigma).VLPswereharvestedat28hposttransfectionbylayeringclariﬁed
cellculturesupernatantoveracushionof30%sucroseinNTEbuffer(1M
sodium chloride, 0.1 M Tris, 0.01 M EDTA, pH 7.4) and centrifuging for
2 h at 4°C and 25,000 rpm in an SW28 rotor (Beckman). Pellets were
resuspended in PBS, and HA protein content was assessed by Western
blottinginparallelwithperformingserialdilutionsofaknownamountof
gradient-puriﬁed PR8 or HK68 virus (prepared as described in reference
24). VLPs shown in Fig. 4 were produced in the presence of exogenous
trypsin, while those used to boost mice were produced without the addi-
tion of trypsin.
Mouse vaccine challenge experiment. Female, 6- to 8-week-old,
C57BL/6 mice (Charles River Laboratories) were initially vaccinated by
intramuscular administration of plasmid DNA, followed immediately by
the application of electrical stimulation (TriGrid delivery system; Ichor
Medical Systems) (25, 26). The spacing of the TriGrid electrode array is
2.5 mm, and the electrical ﬁeld is applied at an amplitude of 250 V/cm of
electrode spacing for six pulses for a total duration of 40 ms applied over
a 400-ms interval. Each DNA vaccination comprised 37.5 g of pGag-
EGFPaloneorincombinationwith75gofpDZPR8HA,pCAGGSPR8
4G,orpCAGGSHK684G.Threeweekslater,aDNAboostwasperformed
byfollowingthesameprocedure.FiveweeksaftertheseconddoseofDNA
wasadministered,themicewereboostedasecondtimewithVLPs.Forthe
HA-containing VLPs, HA content was normalized such that each mouse
received approximately 150 ng HA protein. Prior to intraperitoneal ad-
ministration, VLP suspensions were combined in a 1:1 ratio and emulsi-
ﬁed with complete Freund’s adjuvant (Pierce). Mice were challenged
3 weeks after the VLP boost via intranasal inoculation of two 50% mouse
lethal doses (MLD50) of PR8 virus in a total volume of 50 l PBS. Body
weight was monitored daily, and mice losing more than 25% of their
initial weight were sacriﬁced and scored as dead.
Serologicalassays.Serawerecollectedfrommiceimmediatelybefore
challenge and at 21 days postchallenge. To remove nonspeciﬁc inhibitors
of hemagglutination, trypsin-heat-periodate treatment was performed as
describedpreviously(27).Forhemagglutinationinhibition(HAI)assays,
all sera from each vaccination group were pooled; for ELISAs, sera col-
lectedfromindividualmicewereevaluatedseparately;andforneutraliza-
tion assays, the two serum samples in each group exhibiting the highest
titers by ELISA were pooled. HAI assays were carried out according to
standard methods as described previously (27). For neutralization assays,
2-fold serial dilutions of treated sera were mixed with 10 50% tissue cul-
ture infective doses (TCID50) of PR8 virus and incubated for 45 min at
37°C.AfterbeingwashedwithPBS,MDCKcellswereinoculatedwiththe
virus-antibodymixtures.Followinga45-minincubation,serum-freeme-
dium supplemented with 1 g/ml TPCK-treated trypsin and 3% bovine
serum albumin was added to each well. Cells were incubated at 37°C and,
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growth by hemagglutination assay. For ELISAs, 96-well plates (Costar)
were coated with 0.25 g per well of PR8 virus or with 0.1 g per well of
puriﬁed recombinant HA protein in PBS. PR8 virus for this purpose was
prepared from allantoic ﬂuid by concentration through a 30% sucrose
cushionaspreviouslydescribed(27).TherecombinantHAproteinsofthe
A/California/04/2009, A/Viet Nam/1203/2004, and A/Singapore/1/1957
viruses were obtained from BEI Resources; the A/Hong Kong/1/1968 HA
was the generous gift of Ian Wilson; and the A/New Caledonia/20/99 HA
was purchased from Feldan-Bio. Fivefold serial dilutions of antisera were
incubatedontheplates,andafterextensivewashing,boundantibodywas
detected with an alkaline phosphatase-linked anti-mouse IgG antibody
(Caltag)andp-nitrophenylphosphate(PNPP)substrate(Sigma).Ineach
assay,arabbitimmuneserumraisedagainstwholePR8viruswasincluded
as a positive control, and serum obtained from a naive C57BL/6 mouse
was included as a negative control.
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